84 patients with adhesive capsulitis were randomized to receive ultrasound-guided hydrodilation with 40mg of triamcinolone acetonide (n=42) or 10mg of triamcinolone acetonide (n=42). The primary outcome of interest was pain and disability as measured by the Shoulder Pain and Disability Index (SPADI). Secondary outcomes of interest included pain on a Visual Analog Scale (during rest, motion, at night), range of motion (abduction, external rotation, internal rotation, flexion) and the incidence of adverse events. Outcomes were assessed up to 12 weeks post-injection. No significant differences were observed between the two groups in the change from baseline in SPADI scores at all time-points. Similarly, the change from baseline in VAS pain at rest and at night, as well as all range of motion results, were not statistically significantly different between groups. The improvement in pain during motion scores was significantly better in the 10mg group, however, the baseline scores were significantly lower in the 40mg group to begin with, which could have influenced this result. No adverse events were reported.